Osteoporosis screening, HRT "reasonably cost-effective," OTA says.
This article was originally published in The Gray Sheet
Executive Summary
OSTEOPOROSIS SCREENING, HORMONE REPLACEMENT THERAPY "REASONABLY COST-EFFECTIVE" as prophylaxis against hip fracture and heart disease, an Aug. 29 Office of Technology Assessment background paper maintains. Entitled "Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy," the background paper was requested by the Senate Special Committee on Aging and the House Select Committee on Aging. The analysis looks at several osteoporosis treatment options, focusing primarily on two regimens that call for either bone mineral density screening coupled with targeted HRT or, alternatively, HRT for all post-menopausal women.
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.